Journal: Journal of Alzheimer's disease : JAD

Article Title: Dysfunctional Bladder Morphology and Functional Impairments Are Identified in the Alzheimer’s Disease APP NL−G−F/NL−G−F Murine Model

doi: 10.3233/JAD-230547

Figure Lengend Snippet: Immunoblot analysis of bladder neurotransmitters and receptors. A) schematic illustration of bladder innervation, neurotransmitters, and receptors. B) Protein levels of TH, ChAT, nNOS, M2mAChR, M3mAChR, and β2AR in 4- and 10-month-old APP KI bladders and age-matched WT controls were examined by western blot. β-actin was used to verify equal loading. Blot measurements are in kilodaltons (kDa). C) Bar graphs show quantification of relative protein levels based on western blots shown in B. Bar graphs are from at least 6 animals in each group. n = 3 independent experiments; two or three animals in each group were compared side by side; * p < 0.05, ** p < 0.01; two-way ANOVA with Sidak posthoc multiple comparisons test. Values are expressed as mean ± SEM.

Article Snippet: The membranes were probed with the following primary antibodies and their dilutions: APP-C (1 : 1,000, Sigma, cat# A8717); BACE1 (1 : 1,000); tyrosine hydroxylase (TH) (1 : 500, Millipore, cat# AB152); ChAT (1 : 1,000, Cell Signaling, cat# 27269); nNOS (1 : 1,000, Cell Signaling, cat# 4231); M2mAChR (1 : 1,000, abcam, cat# ab109226); M3mAChR (1 : 1,000, Invitrogen, cat# PA5–85322); β2AR (1 : 500, Bioss, cat# bs-21455R); and β-actin (1 : 10,000, Sigma, cat# A5441).

Techniques: Western Blot

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.

doi: 10.1016/j.biopha.2021.112411

Figure Lengend Snippet: Fig. 2. Relative mRNA expression of cardiac β1-AR, β2-AR, GRK2, and GRK3 in rats treated with P. Note a statistically significant decrease of GRK2 mRNA levels in rats treated with paroxetine, 10 mg/kg/day p.o. Data represent the mean of five rats ± SEM. *p < 0.05 vs. control group (One-way ANOVA fol lowed by Tukey’s multiple comparisons). β-AR, beta-adrenergic receptor; GRK, G protein-coupled receptor kinase.

Article Snippet: Immunohistochemistry was performed manually on the 5 μm-thick sections, according to the manufacturer’s instructions using the specific monoclonal antibodies against CD68 (DAKO, clone PG-M1, dilution 1:50) Leukocyte common antigen LCA IHC (DAKO, clone 2B11 +PD7/26, dilution 1:200), β1-AR (Elabscience®, ADRB1 polyclonal antibody, dilution 1:200), β2-AR (Elabscience®, ADRB2 polyclonal antibody, dilution 1:200), GRK2 (Elabscience®, GRK2 polyclonal antibody, dilution 1:300), and GRK3 (Elabscience®, GRK3 polyclonal antibody, dilution 1:300).

Techniques: Expressing, Control

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.

doi: 10.1016/j.biopha.2021.112411

Figure Lengend Snippet: Fig. 6. Representative photomicrographs of immunohistochemical analysis showing β1-AR and β2-AR. Note decreased immunoreactivity in DOX+P rats. β-AR, beta- adrenergic receptor; DOX, doxorubicin; P, paroxetine.

Article Snippet: Immunohistochemistry was performed manually on the 5 μm-thick sections, according to the manufacturer’s instructions using the specific monoclonal antibodies against CD68 (DAKO, clone PG-M1, dilution 1:50) Leukocyte common antigen LCA IHC (DAKO, clone 2B11 +PD7/26, dilution 1:200), β1-AR (Elabscience®, ADRB1 polyclonal antibody, dilution 1:200), β2-AR (Elabscience®, ADRB2 polyclonal antibody, dilution 1:200), GRK2 (Elabscience®, GRK2 polyclonal antibody, dilution 1:300), and GRK3 (Elabscience®, GRK3 polyclonal antibody, dilution 1:300).

Techniques: Immunohistochemical staining

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Article Title: Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.

doi: 10.1016/j.biopha.2021.112411

Figure Lengend Snippet: Fig. 7. Relative mRNA expression of cardiac β-1 AR, β-2 AR, GRK2, GRK3, ARRB1, and ARRB2 in DOX- and DOX+P -treated rats. Note a statistically significant increase of GRK2 and GRK3 mRNA levels in DOX-HCM rats, a statistically significant increase of β1-AR and β2-AR mRNA levels, and a statistically significant decrease of GRK2 and GRK3 mRNA levels in DOX+P-treated rats. Data represent the mean of at least 7 rats ± SEM.*p < 0.05; * *p < 0.01 vs. control group, †p < 0.05; ††p < 0.01 vs. DOX-HCM, #p < 0.05; ##p < 0.01 vs. DOX-DCM (One-way ANOVA followed by Tukey’s multiple comparisons or Kruskal–Wallis ANOVA followed by Mann–Whitney U test for nonparametric data). β-AR, beta-adrenergic receptor; DCM, dilated cardiomyopathy; DOX, doxorubicin; HCM, hypertrophic cardiomy opathy; GRK, G protein-coupled receptor kinase; P, paroxetine.

Article Snippet: Immunohistochemistry was performed manually on the 5 μm-thick sections, according to the manufacturer’s instructions using the specific monoclonal antibodies against CD68 (DAKO, clone PG-M1, dilution 1:50) Leukocyte common antigen LCA IHC (DAKO, clone 2B11 +PD7/26, dilution 1:200), β1-AR (Elabscience®, ADRB1 polyclonal antibody, dilution 1:200), β2-AR (Elabscience®, ADRB2 polyclonal antibody, dilution 1:200), GRK2 (Elabscience®, GRK2 polyclonal antibody, dilution 1:300), and GRK3 (Elabscience®, GRK3 polyclonal antibody, dilution 1:300).

Techniques: Expressing, Control, MANN-WHITNEY